Your session is about to expire
← Back to Search
Combination Therapy for Triple Negative Breast Cancer
Study Summary
This trial is testing 3 different combinations of drugs or 1 drug by itself to see if it can effectively treat patients with a certain type of breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Participants must have certain test results within a certain range.My breast cancer has spread, is triple-negative, and lacks certain hormone receptors and HER2.I cannot swallow pills or have a stomach condition that affects medication absorption.I will use a condom during and after treatment as required.I have never been treated with PARP inhibitors like olaparib.My condition is critical due to organ failure.I am 18 years old or older.I am currently taking certain medications.My triple-negative breast cancer may or may not have a BRCA mutation.My tumor shows high levels of androgen receptor.I have been diagnosed with MDS/AML or show signs of these conditions.I have active brain metastases or carcinomatous meningitis.I had another cancer but was treated successfully and have been cancer-free for 5 years or more.I am currently taking hormone therapy for a condition that is not cancer.I have not had major surgery recently.I have received cancer treatment within the required time frame.I am not currently receiving any cancer treatments.I am currently on antibiotics for an infection.I am considered at high medical risk due to certain health conditions.You have a weakened immune system, possibly due to HIV or AIDS.I have had a bone marrow or double cord blood transplant.I have active hepatitis B or C.You have had allergic reactions to certain medications in the past.Your resting heart test shows uncontrolled, possibly fixable heart problems.I am not excluded by the drug's specific criteria.I have recovered from side effects of previous treatments, except for hair loss.I agree to have a tumor biopsy after 2 weeks of starting olaparib treatment.I have a tumor that can be measured and biopsied.I have received treatments for breast cancer that has spread.I am fully active and can carry on all pre-disease activities without restriction.
- Group 1: Arm I (olaparib, durvalumab)
- Group 2: Arm III (olaparib, capivasertib)
- Group 3: Arm II (olaparib, selumetinib)
- Group 4: Arm IV (ceralasertib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions can be alleviated with Olaparib?
"Olaparib is a common option for those seeking to treat their medical condition. It has also been applied to combat pharmacotherapy, primary peritoneal cancer and advance directives."
What additional research has been conducted into the efficacy of Olaparib?
"Currently, there are 486 experiments researching the effectiveness of Olaparib. Of those trials, 75 are in their third phase with a bulk of them located near Houston, Texas; however, 19978 sites across the world offer these clinical studies."
Is this an unprecedented attempt at treatment?
"Olaparib has been under scrutiny by the scientific community since 2005, when AstraZeneca conducted an initial trial involving 98 patients. Subsequently, Phase 1 drug approval was granted and today there are 484 live studies for Olaparib occurring in 1846 cities across 65 countries."
What is the intake capacity for this clinical research project?
"Affirmative. According to clinicaltrials.gov, this medical research is presently enrolling patients who meet the criteria. This study was originally posted on December 12th 2018 and its information has been updated as recently July 29th 2022. 132 individuals are sought across a single site for participation in the investigation."
To what extent might Olaparib endanger patients?
"Taking into account that Olaparib is currently in Phase 2 of its clinical trial, our team at Power has rated the safety of this medication as a 2. While there are some data points suggesting it is safe to use, none have so far proven efficacy."
Is this research actively soliciting participants?
"Affirmative. The information hosted on clinicaltrials.gov reveals that this medication trial, which was initially posted December 12th 2018, is presently looking for suitable participants. 132 individuals are needed to take part in the study at 1 medical centre."
Share this study with friends
Copy Link
Messenger